NewsOutcome of Episurf Medical’s rights issue

The subscription period for Episurf Medical’s new issue of A and B shares with preferential right for the company’s shareholders ended on 13 March 2017 and the final outcome shows that the rights issue was subscribed for by shareholders to approximately 91.5 per cent, which means that Episurf Medical receives approximately SEK 109.5 million before issue related costs.

“The rights issue represents a significant capital contribution for Episurf and it enables us to execute upon our growth plan. We are seeing a great interest in our technology and our products and an increasing number of orthopaedic surgeons are turning to our solution for treatment of patients with cartilage and bone lesions of the knee joint. Our clinical portfolio is growing steadily and to date, approximately 180 patients have been treated with our implants. In step with this we are strengthening our opportunities to establish Episealer and Epioscopy on the global market where we see a great interest in our technology. Further, we can happily conclude that there is a significant interest for our company among investors given the solid support in the capital issue from existing shareholders as well as new investors” says Pål Ryfors, acting CEO of Episurf.

Click here to read the full press release >>

For more information, please contact:
Pål Ryfors, acting CEO and CFO, Episurf
Tel: +46 70 962 36 69
Email: pal.ryfors@episurf.com